These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 27207551)

  • 1. Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism.
    Briand F; Mayoux E; Brousseau E; Burr N; Urbain I; Costard C; Mark M; Sulpice T
    Diabetes; 2016 Jul; 65(7):2032-8. PubMed ID: 27207551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
    Xu L; Nagata N; Nagashimada M; Zhuge F; Ni Y; Chen G; Mayoux E; Kaneko S; Ota T
    EBioMedicine; 2017 Jun; 20():137-149. PubMed ID: 28579299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin Protects Cardiac Mitochondrial Fatty Acid Metabolism in a Mouse Model of Diet-Induced Lipid Overload.
    Makrecka-Kuka M; Korzh S; Videja M; Vilks K; Cirule H; Kuka J; Dambrova M; Liepinsh E
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):791-797. PubMed ID: 32424653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
    Kern M; Klöting N; Mark M; Mayoux E; Klein T; Blüher M
    Metabolism; 2016 Feb; 65(2):114-23. PubMed ID: 26773934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats.
    Takeshige Y; Fujisawa Y; Rahman A; Kittikulsuth W; Nakano D; Mori H; Masaki T; Ohmori K; Kohno M; Ogata H; Nishiyama A
    Hypertens Res; 2016 Jun; 39(6):415-22. PubMed ID: 26818652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation.
    Benetti E; Mastrocola R; Vitarelli G; Cutrin JC; Nigro D; Chiazza F; Mayoux E; Collino M; Fantozzi R
    J Pharmacol Exp Ther; 2016 Oct; 359(1):45-53. PubMed ID: 27440421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
    Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
    Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol.
    Jojima T; Sakurai S; Wakamatsu S; Iijima T; Saito M; Tomaru T; Kogai T; Usui I; Aso Y
    Int J Cardiol; 2021 May; 331():243-248. PubMed ID: 33556413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus.
    Jordan J; Tank J; Heusser K; Heise T; Wanner C; Heer M; Macha S; Mattheus M; Lund SS; Woerle HJ; Broedl UC
    J Am Soc Hypertens; 2017 Sep; 11(9):604-612. PubMed ID: 28757109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin for the treatment of type 2 diabetes.
    Jahagirdar V; Barnett AH
    Expert Opin Pharmacother; 2014 Nov; 15(16):2429-41. PubMed ID: 25301180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters.
    Briand F; Thieblemont Q; Muzotte E; Sulpice T
    Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):13-23. PubMed ID: 23139291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
    Ojima A; Matsui T; Nishino Y; Nakamura N; Yamagishi S
    Horm Metab Res; 2015 Aug; 47(9):686-92. PubMed ID: 25611208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitors: new reports.
    Med Lett Drugs Ther; 2015 Oct; 57(1479):139-40. PubMed ID: 26445203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
    Dailey GE
    Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The SGLT2 inhibitor empagliflozin: results of EMPA-REG OUTCOMER trial].
    Okamura T; Koiwai K
    Nihon Yakurigaku Zasshi; 2016; 148(5):282. PubMed ID: 27803444
    [No Abstract]   [Full Text] [Related]  

  • 18. Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity.
    Liu Y; Xu J; Wu M; Xu B; Kang L
    Lipids Health Dis; 2021 Jan; 20(1):5. PubMed ID: 33436015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients.
    Al Jobori H; Daniele G; Adams J; Cersosimo E; Triplitt C; DeFronzo RA; Abdul-Ghani M
    Diabetes Obes Metab; 2017 Jun; 19(6):809-813. PubMed ID: 28128510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice.
    Pennig J; Scherrer P; Gissler MC; Anto-Michel N; Hoppe N; Füner L; Härdtner C; Stachon P; Wolf D; Hilgendorf I; Mullick A; Bode C; Zirlik A; Goldberg IJ; Willecke F
    Sci Rep; 2019 Nov; 9(1):17937. PubMed ID: 31784656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.